API
< Back to situations

[ORGANIZATION]

Sellas Life Sciences

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US]

Sellas Life Sciences cancer vaccine clinical trials

2 clusters · 4 sources · last updated

Latest: Galinpepimut-S vaccine reduces leukemia death risk by 41%

Sellas Life Sciences reported successful results from its Phase 3 REGAL study for the peptide vaccine Galinpepimut-S (GPS), intended to treat acute myeloid leukemia (AML). The study met its primary endpoint of statistica